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Objectives. The aim of this study was to evaluate the efficacy of
a single dose of intravenous amiodarone in facilitating defibrilla-
tion of ventricular fibrillation refractory to lidocaine and epineph .
One plus direct current countershocks in experimental acute
myocardial infarction .
Background, Amiodarone has been hailed as the most effective
single antiarrhythmic drug for the treatment of ventricular ar-
rhythmias . However, intravenous amiodarone has only sporadi-
cally been used in the defibrillation of ventricular fibrillation in
acute my
	
dial infarction .
Afelhods. Acute myocardial infarction was induced in 60 dogs
by ligation of the proximal left anterior descending coronary
artery for 2 h . Animals that developed spontaneous ventricular
fibrillation were treated with lidocaine and epinephrine plus five
direct-current countershocks. Dogs with ventricular fibrillation
refractory to this regimen were randomized to further treatment
with additional intravenous administration of epinephrine and
Amiodarone therapy is usually reserved for patients with
drug-resistant life-threatening tachyarrhythmias (1-12) be-
cause of the potential severity of its many adverse effects
(13-!5) and its unusual pharmacokinetics (16- .~20) .
Like other antiarrhythmic drugs (2112) that exert clinical
prophylactic and therapeutic elects against ventricular fi-
brillation, amiodarone has been characterized by its ability
to raise the experimental ventricular fibrillation threshold
(23) . It is also more effective than bretylium in suppressing
reperfusion arrhythmias in dogs (24),
Intravenous amiodarone has been used with remarkable
efficacy in critically ill patients with recurrent ventricular
arrhythmias (5,25,26). It has also been used during pro-
longed in-hospital resuscitation from refractory cardiac ar-
rest due to ventricular tachycardia/fibrillation (27-29) . How-
ever, intravenous amiodarone has never been utilized in a
randomized manner in acute myocardial infarction for the
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bolus lidocalne plus ,2515 direct-current countershocks (group 1) or
administration of amiodarone q 10 mg/kg body weight intrave-
nously, followed by defibrillation with direct-current counter-
shack (group 11) .
Results . Sixteen (27%) of the 60 dogs its which the protocol was
attempted developed spontaneous ventricular fibrillation 21 min
after ligation and were included in the study . Lidocaine and
epinephrine plus five direct-urrent countershocks succeeded in
converting ventricular fibrillation in one dog (6%). The other 15
dogs were randomized to group 1 (8 dogs) or group B (7 dogs) .
Defibrillation was achieved in one of the eight dogs in group I and
in six of the seven dogs in group 11 (p < 0,005) .
Conclusions . In an experimental model of acute ischemia,
intravenous andodarone (10 mg/kg) influences positively the re-
sponse to defibrillation of ventricular fibrillation refractory to
lidocaine and epinephrine plus direct current countershocks .
(j Am Coil Cardiol 1994,23.-253-8)
defibrillation of ventricular fibrillation refractory to epineph-
rine and lidocaine plus direct current countershocks .
Thus, the purpose of this study was to determine the
efficacy of a single dose of intravenous arniodarone given as
a bolus in facilitating defibrillation of spontaneous ventricu-
lar fibrillation refractory to lidocaine and epinephrine plus
direct current countershocks in experimental acute myocar-
dial infarction and to evaluate the hemodynamic variables of
the animals after restoration of sinus rhythm .
Methods
Sixty male or female mongrel dogs weighing 18 to 35 kg
were anesthetized with sodium pentobarbital (30 mg/kg body
weight), intubated, and ventilated with room air with the use
of a volume ventilator, adjusted to provide normal pH and
Pco2. Electrocardiographic (ECG) limb leads were attached
and monitored continuously on an oscilloscope . A cutdown
was performed on one femoral vein and a venous infusion
catheter for crystalloid administration and blood sampling
for sodium, potassium and amiodaronc level determinations
was established. After a left thoracotomy was performed by
using cautery and shears, the heart was isolated and sus-
pended in a pericardial cradle . The proximal left anterior
0735.09719456-00
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descending coronary artery was dissected free and a
lubri-
cated umbilical tape tunneled underneath
. The tape was then
used to occlude the vessel for 2 h. A catheter was placed into
the aortic arch and an arterial pressure line established for
blood pressure monitoring throughout the experiment . An-
other catheter was placed into the left atrium for left atrial
pressure recording. Adequate intravascular volume was
maintained with lactated Ringer solution . All experiments
conformed to the "Position of the American Heart Associ-
ation on Research Animal Use" adopted by the Association
in November 1984 (30).
Arrhythmia treatment protocol. All dogs were treated
prophylactically with lidocaine 1 .5 mg/kg bolus and contin-
uous infusion of 1 mg/min throughout the experiment . Dogs
that developed ventricular fibrillation during the 2 h of
coronary artery ligation first received "standard treatment"
(Fig. 1). First, a direct-current countershock of 50 J was
delivered by two, 8-cm diameter, spoon-shaped electrodes
secured to the heart. If sinus rhythm was not restored, a
second direct-current impulse of 50 J was delivered . If
ventricular fibrillation persisted, intravenous sodium bicar-
bonate was used to maintain blood at pH ?7 .3 . During
ventricular fibrillation ventilation was provided by the vol-
ume ventilator, which was adjusted to the levels maintained
before the onset of ventricular fibrillation . A third direct-
current countershock of 50 J was then delivered . Epineph-
rine (1 .0 mg) was given intravenously and direct cardiac
massage was performed for I to 2 min before a fourth
direct-current impulse of 50 J was delivered . A fifth defibril-
lation attempt was made before ventricular fibrillation %_as
characterized as refractory. Cardiac massage was instituted
to maintain circulation during fibrillation . The dogs were
then randomized into two groups (Fig . 2). In group 1, up to
15 defibrillation attempts with direct-current countershocks
of 50 J each were allowed if defibrillation was not obtained
while the dog was receiving conventional therapy (additional
intravenous administration of bicarbonate, epinephrine and
bolus lidocaine) . In group II, intravenous amiodarone
Figure 1
. Ventricular fibrillation treatment algorithm . IV = intrave-
(10 mg/kg) was first administered to the animals over 30 s nously. Numbers in parentheses indicate number of defibrillation
because of the emergency situation, then cardiac massage
attempts.
was performed for 1 min and followed by attempted defibril-
lation with direct-current countershocks. Dogs that did not
develop spontaneous ventricular fibrillation during the 2 h of
coronary artery ligation continued on protocols of myocar-
dial salvage by reperfusion in combination with intraaortic
balloon pump assistance (unpublished data) .
Heart rate and hemody is variables. Heart rate, in-
traarterial blood pressure and left atrial pressure were re-
corded .
A ne assay. Blood samples drawn within 30 min
after amiodarone bolus administration and defibrillation of
refractory ventricular fibrillation were centrifuged, plasma-
separated and frozen . Samples were assayed for amiodarone
by high pressure liquid chromatography (16) using n-hexane
extracts of serum and the 2-ethyl,3-(4-dimethylamino-
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ethoxy,3,5-diodo,benzoyl) as internal standard and an Ami-
no-sil-x-1 column (Perkin-Elmer) .
A standard curve of free drug serum containing 0 .5, 1 .0
and 2 mg/liter of amiodarone was prepared and used to
calculate the concentration of the drug in the unknown
samples. The reproducibility within I day was estimated by
extracting 10 replicate serum samples containing 0.5, 1 and
2 mg/liter of amiodarone. The coefficient of variation of
concentration ratio of amiodarone : internal itandard was
<4%, whereas the lower limit of quantitation was 0 .1 mg/
liter. These findings were consistent with previous results
(16) .
Tissue samples of amiodarone from both infarcted and
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Figure 2. Standard treatment (up to five attempts)
for defibrillation of ventricular fibrillation . Conven-
tional therapy includes additional epinephrine and
bolus lidocaine in addition to up to 15 defibrillation
attempts . '1p -- 0 .005 versus group 1 .
noninfarcted myocardium were also obtained at the termi-
nation of the experiment, frozen, homogenated with metha-
nol and further extracted with n-hexane as described previ-
ously (31). Amiodarone concentration was then determined
under the same conditions as for serum analysis (16) .
Analysis of data. Heart rate and hemodynamic variables
were averaged and presented as mean value ± SD. A paired
r test was used to assess differences am..Gag the data sets for
changes in variables (after amiodaronc administration and
defibrillation versus control stage [before ventricular fibril-
lation occurred]). The Fisher exact test was used to detect
diff,-rences between groups. Significance was claimed at a
level of p < 0 .05 for two-tailed hypotheses .
Results
The protocol was attempted in 60 dogs . The mean heart
rate for all dogs at baseline before artery ligation was 164 ±
38 beats/min; systolic blood pressure and left atrial pressure
were 140 ± 25 and 9 ± 4.3 mm Hg, respectively . Spontane-
ous ventricular fibrillation occurred in 16 dogs (27%) within
21 ± 17 min (range I to 31) after coronary artery ligation .
Sinus rhythm was restored with direct-current ccunter-
shocks in one dog . In 15 dogs, ventricular fibrillation per-
sisted even after the fifth defibrillation attempt despite ad-
ministration of "standard treatment" with intravenous
lidocaine, epinephrine and sodium bicarbonate. Blood gases
and serum electrolytes were monitored and maintained
within normal limits .
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Defibrillation of refractory venntricular fibrillation . The 15
dogs with refractory ventricular fibrillation were randomly
allocated as described . Group I (eight dogs) received -corr-
ventional therapy": additional epinephrine and bolus lido-
caine and up to 15 defibrillation attempts with direct-current
countershocks of 50 J each . Group 11 (seven dogs) received
intravenous amiodarone (10 mg1kg over 30 s) and then
defibrillation attempts using direct-current impulses of 50 J
each. Conversion to sinus rhythm occurred in one of the
eight dogs in group I versus six of the seven dogs in group II
(p < 0.005, Fig. 2). Of the seven dogs in group II, 6 had
successful defibrillation with I to 3 direct-current counter-
shocks ; the dog that did not have conversion to sinus rhythm
received up to 15 direct-current countershocks . The time
elapsed between the onset of ventricular fibrillation and the
time of successful defibrillation in the preceding experiments
was estimated to be approximately 10 min .
Heart rate and hemodynamic response (Table 1) . After
amiodarone administration and successful defibrillation, the
6 dogs with refractory ventricular fibrillation had a signifi-
cant decrease in blood pressure and heart rate and a signif-
icant increase in left atrial pressure . However, all dogs
required epinephrine infusion to maintain heart rate and
blood pressure .
Arniodarone plasma and myocardial concentration . At
23 ± 13 min after conversion of refractory ventricular
fibrillation to sinus rhythm, mean plasma concentration of
amiodarone was 2 .53 ± 1 .88 y&A (range 0.8 to A I [n = 4])
.
Myocardial concentration at the infarcted area was
2:6
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Table 1
. Hemodynainic Variables After Successful Defibrillation
in Group II (dogs treated with amiodarone)
a
Mean 12 ± 3 min after defibrillation .
73 .3
±
35 .1
tg per g of myocardial tissue and at the
noninfarcted area 120.2 ± 20.6 pg per g of tissue (p < 0 .03,
n = 5) . The myocardial/plasma concentration ratio at 23 ±
13 min after amiodarone administration was 28 .97 at the
infarcted area and 47.51 at the noninfarcted area .
Discussion
This study evaluated the efficacy of amiodarone in facil-
itating defibrillation of spontaneous ventricular fibrillation
refractory to lidocaine and epinephrine plus direct-current
countershocks in experimental acute myocardial infarction
(32) . In this setting amiodarone administered intravenously
at a dose of 10 mg/kg influenced beneficially the response of
refractory ventricular fibrillation to defibrillation . Thus, six
(86%) of the seven dogs with refractory ventricular fibrilla-
tion versus one (13%) of the eight given conventional ther-
apy had conversion to sinus rhythm . The high incidence of
refractory ventricular fibrillation observed may be explained
by the prophylactic use of lidocaine and the large extent of
myocardial ischemia obtained. Thus, the ischemic area of
the myocardium calculated using gentian violet, which sep-
arates the nonischemic from ischemic area of the left ven-
tricle, in 22 dogs that completed the other protocols (unpub-
lished data) was found to be 36 ± 10% of the left ventricle .
Furthermore, six more dogs died of electromechanical dis-
sociation .
Effects of aln ne on ventricular arrhyth ias. Oral
amiodarone has been found to be effective in a wide array of
supraventricular and ventricular tachyarrhythmias. The ac-
tuarial incidence of successful amiodarone therapy in pre-
venting recurrent ventricular tachycardia and recurrent ven-
tricular fibrillation was 52 ± 7% at 12 months and 28 ± 9% at
24 months in a study of 77 patients (13) . In another study
(15), 55% (34 of 62) of patients with these arrhythmias, were
treated successfully with amiodarone over an average of
approximately I year of follow-up (15) . However, the pro-
longed time to maximal clinical efficacy of oral amiodarone
has important implications for some patients, such as those
with frequent recurrence of life-threatening arrhythmias
unresponsive to direct countershock .
In contrast to oral amiodarone, intravenously adminis-
tered amiodarone showed rapid efficacy (0 to 84 h) in 58 .5%
of patients with recurrent ventricular tachycardia and ven-
tricular fibrillation refractory to other drugs (5) . It was also
used safely and effectively for the termination of sustained
ventricular tachycardia (9) . However, close supervision and
continuous monitoring not only of the ECG but also of blood
pressure are recommended during intravenous amiodarone
administration as hypotension may occur . Intravenous ami-
odarone used in a canine reperfusion arrhythmia model
rapidly suppressed sustained ventricular tachycardia or ven-
tricular fibrillation (24) . This effect of amiodarone is signifi-
cant because reperfusion arrhythmias ha-.- - become increas-
ingly important now that a variety of acute interventions are
utilized to prevent myocardial infarction or limit infarct size
by restoring myocardial blood flow after a period of isch-
emia. Although many reports are available on the efficacy of
intravenous amiodarone to prevent recurrent ventricular
tachycardialventricular fibrillation, the drug has been used
only sporadically to facilitate defibrillation of ventricular
fibrillation.
Thus, Maheswaran et al . (29) described a patient with
intractable ventricular fibrillation after a digoxin overdose
who was successfully treated with intravenous amiodarone.
In another report (28), sinus rhythm was restored by direct-
current countershock after intravenous administration of
amiodarone (200 mg for 30 s) in a patient who had had
persistent ventricular fibrillation after 75 min of attempted
resuscitation and 15 defibrillation attempts . More recently,
Williams and associates (27) reported on 14 patients given
intravenously administered amiodarone during prolonged
in-hospital resuscitation from refractory cardiac arrest due
to ventricular tachycardia or ventricular fibrillation . Eleven
patients survived the prolonged cardiac arrest after receiving
intravenous amiodarone . In 4 of the 11 survivors, sustained
sinus rhythm was restored by a single cardioversion or
defibrillation attempt administered several minutes after
amiodarone administration. In our experimental study, the
underlying cause of ventricular fibrillation was acute myo-
cardial infarction . Our findings support previous data (27-29)
that amiodarone given intravenously facilitates the defibril-
lation of ventricular fibrillation .
Mechanisms of action of amiodarone . Amiodarone may
produce its antiarrhythmic and antifibrillatory actions by
decreasing dispersion of refractoriness and restoring homo-
geneous patterns of conduction (33) . Intravenous amio-
darone exerts immediate effects on fast channel activity (34),
blocks slow channel conductance (35) and possesses acute
alpha- and beta-blocking properties (36) .
Experimental data from a feline model of acute ischemia
(37) demonstrated that ventricular tachycardia/fibrillation
occurred in all animals that underwent left stellate ganglion
stimulation superimposed on transient left anterior descend-
ing coronary artery occlusion but in none pretreated with
intravenous amiodarone. The investigators concluded that
amiodarone's most important protective electrophysiologic
action in this model was acute onset of antiadrenergic
activity .
Procainamide and bretylhumn for defibrillation of ventricu-
lar fibrillation. Procainamide (38) and bretylium (39-41)
have both been used in successful defibrillation of ventricu-
Control
Period
After
P
Deribrillation° Value
Heart rate (beats/min) 217 ± 18 143 ± 53
< 0.03
Systolic aortic pressure (mm Hg) 149 t 24 115 t 31
< 0 .1
Left atrial pressure (mm Hg} 12 ± 3 31 ± 16
< 0 .05
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far fibrillation . Moreover, amiodarone was found more ef-
fective than bretylium (24) in suppressing reperfusion ar-
rhythmias in dogs, However, no experimental data regarding
procainamide and bretylium in facilitating defbrillalion of
refractory to lidocaine and cpincphrine plus direct-current
countershocks ventricular fibrillation are available for com-
parison with our findings .
Hemodynamic effects of amiodarone . Although in our
experiments amiodarone influenced positively the response
of refractory ventricular fibrillation to defibrillation, the dogs
were hemodynamically unstable after defibrillation and re-
quired epinephrine infusion to maintain heart rate and blood
pressure within acceptable values . Amiodarone may cause
hypotension, presumably because of vasodilation and nega-
tive inotropic effect (33) . However, the worsening of the
hemodynamic variables after defibrillation compared with
pre-fibrillation data may have been a result of the large
ischemic area and the prolonged resuscitation period rather
than a direct adverse effect of intravenous amiodarone .
Myocardial and plasma concentrations of amiodarone .
Myocardial amiodarone concentration at the infarcted area
after defibrillation was 30 times higher than that observed in
plasma at the same time interval. Amiodarone was detected
in the nonperfused myocardium at a concentration of 73 .3
35 .1 lAg per g of myocardial tissue . Detection of amiodarone
in the nonperfused myocardium may be explained by retro-
grade perfusion of the area during direct heart massage .
Other drugs, such as lidocaine (42,43) and procainamide
(44), have also been shown to be distributed in ischemic
areas of myocardium . The mechanisms speculated to explain
drug accumulation were local properties of ischemic myo-
cardium, binding of the drug to molecules such as phospho-
lipids or altered metabolism of the drug in the infarct area .
Myocardial and plasma amiodarone concentrations were
within those reported by Latini et al . (31) .
Limitations of the study . The results of our study should
be extrapolated to the clinical setting only with great cau-
tion . Clinical determinants of ventricular fibrillation are
undoubtedly more complex than those in the experimental
model.
Conclusions . We conclude that intravenous amiodarone
influences positively the response to defibrillation attempts
of ventricular fibrillation refractory to lidocaine and epineph-
rine plus direct current countershocks in a canine model of
experimental acute ischemia. Because clinical outcome may
oe adversely affected by a prolonged period of resuscitation,
these data suggest the use of intravenous amiodarone in
humans with refractory ventricular fibrillation complicating
acute myocardial infarction who require cardiopulmonary
resuscitation and multiple direct-current counters socks .
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